Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$3500

Fibroblast growth factor receptor 4 is a protein encoded by the FGFR4 gene. It is required for normal down-regulation of the expression of CYP7A1, the rate-limiting enzyme in bile acid synthesis, in response to FGF19. The Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) Development market research report provides an in-depth analysis of Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted pipeline therapeutics. The report provides comprehensive information on the Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type.

The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects.

Mechanisms of Action of Fibroblast Growth Factor Receptor 4 Pipeline Market

The mechanisms of action of the Fibroblast Growth Factor Receptor 4 pipeline market are Fibroblast Growth Factor Receptor 4 Inhibitor, Fibroblast Growth Factor Receptor 4 Antagonist, and Fibroblast Growth Factor Receptor 4 Agonist.

Fibroblast Growth Factor Receptor 4 pipeline market, by mechanisms of action

Fibroblast Growth Factor Receptor 4 pipeline market, by mechanisms of action

For more mechanisms of action insights, download a free report sample

Routes of Administration in Fibroblast Growth Factor Receptor 4 Pipeline Market

The routes of administration in the Fibroblast Growth Factor Receptor 4 pipeline market are oral, intravesical, subcutaneous, and intrathecal.

Fibroblast Growth Factor Receptor 4 pipeline market, by routes of administration

Fibroblast Growth Factor Receptor 4 pipeline market, by routes of administration

For more routes of administration insights, download a free report sample

Molecule Types in Fibroblast Growth Factor Receptor 4 Pipeline Market

The molecule types in the Fibroblast Growth Factor Receptor 4 pipeline market are small molecule, recombinant protein, and fusion protein.

Fibroblast Growth Factor Receptor 4 pipeline market, by molecule types

Fibroblast Growth Factor Receptor 4 pipeline market, by molecule types

For more molecule type insights, download a free report sample

Key Fibroblast Growth Factor Receptor 4 Pipeline Market Companies

Some of the key companies in the Fibroblast Growth Factor Receptor 4 pipeline market are Abbisko Therapeutics Co Ltd, Applied Pharmaceutical Science Inc, Astellas Pharma Inc, Bayer AG, Betta Pharmaceuticals Co Ltd, BioArdis, LLC, Blueprint Medicines Corp, BridgeBio Pharma Inc, BridGene Biosciences Inc, and Bristol-Myers Squibb Co.

Fibroblast Growth Factor Receptor 4 pipeline market, by companies

Fibroblast Growth Factor Receptor 4 pipeline market, by companies

To know more about key companies, download a free report sample

Market report overview

Mechanisms of Action Fibroblast Growth Factor Receptor 4 Inhibitor, Fibroblast Growth Factor Receptor 4 Antagonist, and Fibroblast Growth Factor Receptor 4 Agonist
Routes of Administration Oral, Intravesical, Subcutaneous, and Intrathecal
Molecule Types Small Molecule, Recombinant Protein, and Fusion Protein
Key Companies Abbisko Therapeutics Co Ltd, Applied Pharmaceutical Science Inc, Astellas Pharma Inc, Bayer AG, Betta Pharmaceuticals Co Ltd, BioArdis, LLC, Blueprint Medicines Corp, BridgeBio Pharma Inc, BridGene Biosciences Inc, and Bristol-Myers Squibb Co

Scope

This report provides:

  • A snapshot of the global therapeutic landscape of Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1).
  • Reviews of Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products based on various stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
  • Reviews of key players involved in Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) therapeutics and enlists all their major and minor projects.
  • Assessment of Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA), and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news and deals related to pipeline therapeutics for Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1).

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.
  • Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
  • Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1).
  • Identify the use of drugs for target identification and drug repurposing.
  • Identify potential new clients or partners in the target demographic.
  • Develop strategic initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics.
  • Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) development landscape.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Abbisko Therapeutics Co Ltd
Applied Pharmaceutical Science Inc
Astellas Pharma Inc
Bayer AG
Betta Pharmaceuticals Co Ltd
BioArdis LLC
Blueprint Medicines Corp
BridgeBio Pharma Inc
BridGene Biosciences Inc
Bristol-Myers Squibb Co
Eddingpharm Inc
Eisai Co Ltd
Eli Lilly and Co
EUSOL Biotech Co Ltd
Everest Medicines Ltd
Genosco Inc
H3 Biomedicine Inc
Heilongjiang ZBD Pharmaceutical Co Ltd
ImmunoForge Co Ltd
InnoCare Pharma Ltd
Jacobio Pharmaceuticals Group Co Ltd
Johnson & Johnson
Merck & Co Inc
NGM Biopharmaceuticals Inc
Shouyao Holding Co Ltd
Tyra Biosciences Inc
Vichem Chemie Research Ltd
Zhejiang Hisun Pharmaceutical Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC

2.7.10.1) – Overview

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC

2.7.10.1) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC

2.7.10.1) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC

2.7.10.1) – Companies Involved in Therapeutics Development

Abbisko Therapeutics Co Ltd

Applied Pharmaceutical Science Inc

Astellas Pharma Inc

Bayer AG

Betta Pharmaceuticals Co Ltd

BioArdis LLC

Blueprint Medicines Corp

BridgeBio Pharma Inc

BridGene Biosciences Inc

Bristol-Myers Squibb Co

Eddingpharm Inc

Eisai Co Ltd

Eli Lilly and Co

EUSOL Biotech Co Ltd

Everest Medicines Ltd

Genosco Inc

H3 Biomedicine Inc

Heilongjiang ZBD Pharmaceutical Co Ltd

ImmunoForge Co Ltd

InnoCare Pharma Ltd

Jacobio Pharmaceuticals Group Co Ltd

Johnson & Johnson

Merck & Co Inc

NGM Biopharmaceuticals Inc

Shouyao Holding Co Ltd

Tyra Biosciences Inc

Vichem Chemie Research Ltd

Zhejiang Hisun Pharmaceutical Co Ltd

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC

2.7.10.1) – Drug Profiles

ABSK-011 – Drug Profile

Product Description

Mechanism Of Action

History of Events

ABSK-012 – Drug Profile

Product Description

Mechanism Of Action

History of Events

ABSK-121 – Drug Profile

Product Description

Mechanism Of Action

History of Events

aldafermin – Drug Profile

Product Description

Mechanism Of Action

History of Events

ASP-5878 – Drug Profile

Product Description

Mechanism Of Action

History of Events

BIO-1262 – Drug Profile

Product Description

Mechanism Of Action

History of Events

BPI-43487 – Drug Profile

Product Description

Mechanism Of Action

derazantinib hydrochloride – Drug Profile

Product Description

Mechanism Of Action

History of Events

EDP-317 – Drug Profile

Product Description

Mechanism Of Action

History of Events

erdafitinib – Drug Profile

Product Description

Mechanism Of Action

History of Events

ES-135 – Drug Profile

Product Description

Mechanism Of Action

History of Events

FGFR2/3/4 Inhibitor – Drug Profile

Product Description

Mechanism Of Action

fisogatinib – Drug Profile

Product Description

Mechanism Of Action

History of Events

Fusion Proteins to Agonize FGFR for Metabolic Disorders – Drug Profile

Product Description

Mechanism Of Action

gunagratinib – Drug Profile

Product Description

Mechanism Of Action

History of Events

H-3B6527 – Drug Profile

Product Description

Mechanism Of Action

History of Events

HS-236 – Drug Profile

Product Description

Mechanism Of Action

HZB-1006 – Drug Profile

Product Description

Mechanism Of Action

ICP-105 – Drug Profile

Product Description

Mechanism Of Action

History of Events

infigratinib phosphate – Drug Profile

Product Description

Mechanism Of Action

History of Events

JAB-6343 – Drug Profile

Product Description

Mechanism Of Action

KF-1604 – Drug Profile

Product Description

Mechanism Of Action

History of Events

lenvatinib mesylate – Drug Profile

Product Description

Mechanism Of Action

History of Events

LY-2874455 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Recombinant Protein to Agonize FGFRs for Oral Mucositis – Drug Profile

Product Description

Mechanism Of Action

roblitinib – Drug Profile

Product Description

Mechanism Of Action

History of Events

rogaratinib – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Inhibit FGFR4 for Hepatocellular Carcinoma – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Inhibit FGFR4 for Solid Tumors – Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Antagonize FGFR4 for Hepatocellular Carcinoma – Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit FGFR4 for Childhood Rhabdomyosarcoma, Hepatocellular Carcinoma, and Solid Tumors – Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit FGFR4 for Hepatocellular Carcinoma – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit FGFR4 for Hepatocellular Carcinoma – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit Pan FGFR for Oncology – Drug Profile

Product Description

Mechanism Of Action

SY-4798 – Drug Profile

Product Description

Mechanism Of Action

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC

2.7.10.1) – Dormant Products

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC

2.7.10.1) – Discontinued Products

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC

2.7.10.1) – Product Development Milestones

Featured News & Press Releases

Mar 07, 2022: Taiwan approves Eisai’s Lenvima combo for endometrial carcinoma

Mar 03, 2022: Helsinn Group and BridgeBio Pharma announce update to strategic collaboration to develop, manufacture and commercialize Infigratinib in oncology indications in the U.S.

Feb 08, 2022: Abbisko Therapeutics completes dosing of the first patient in the phase II clinical trial for ABSK011 in combination with an Anti-PD-L1 antibody

Jan 31, 2022: LENVIMA (lenvatinib) in combination with KEYTRUDA (pembrolizumab) approved in Taiwan for the first-line treatment of patients with advanced renal cell carcinoma

Jan 26, 2022: Progression-free survival and overall survival significantly longer with lenvatinib plus pembrolizumab than with chemotherapy in advanced endometrial cancer

Jan 24, 2022: Basilea reports updated interim results for iCCA patients with FGFR2 mutations and amplifications from phase 2 study FIDES-01 at ASCO GI Cancers Symposium

Jan 20, 2022: Results from pivotal phase 3 study 309/KEYNOTE-775 trial of LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) in advanced endometrial carcinoma published in the New England Journal of Medicine

Jan 17, 2022: Eisai to present abstracts on lenvatinib at 2022 ASCO Gastrointestinal Cancers Symposium

Jan 14, 2022: Eisai to present research at the 2022 ASCO Gastrointestinal Cancers Symposium in multiple tumor types from its robust oncology portfolio

Jan 05, 2022: Knight Therapeutics announces approval of Lenvima in Colombia

Dec 24, 2021: LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) approved in Japan for patients with Unresectable, advanced or recurrent endometrial carcinoma that progressed after cancer chemotherapy

Dec 21, 2021: Helsinn Group announces European Medicines Agency’s (EMA) acceptance for review of the marketing authorization application (MAA) for infigratinib for patients with cholangiocarcinoma with fibroblast growth factor receptor 2 fusions or rearrangements

Dec 21, 2021: LianBio announces infigratinib approved under special named patient program for the treatment of cholangiocarcinoma in the pilot zone of Hainan province in China

Oct 19, 2021: Abbisko Therapeutics announces the IND approval by NMPA for phase II clinical trial of ABSK011

Oct 18, 2021: Eisai and Merck & Co Kenilworth, N.J., U.S.A. receive positive EU CHMP opinions for LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) in two different types of cancer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indications, 2022

Number of Products under Development by Indications, 2022 (Contd..1)

Number of Products under Development by Indications, 2022 (Contd..2)

Number of Products under Development by Indications, 2022 (Contd..3)

Number of Products under Development by Indications, 2022 (Contd..4)

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Companies, 2022 (Contd..3)

Products under Development by Companies, 2022 (Contd..4)

Products under Development by Companies, 2022 (Contd..5)

Products under Development by Companies, 2022 (Contd..6)

Products under Development by Companies, 2022 (Contd..7)

Products under Development by Companies, 2022 (Contd..8)

Products under Development by Companies, 2022 (Contd..9)

Products under Development by Companies, 2022 (Contd..10)

Products under Development by Companies, 2022 (Contd..11)

Products under Development by Companies, 2022 (Contd..12)

Products under Development by Companies, 2022 (Contd..13)

Products under Development by Companies, 2022 (Contd..14)

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by Abbisko Therapeutics Co Ltd, 2022

Pipeline by Applied Pharmaceutical Science Inc, 2022

Pipeline by Astellas Pharma Inc, 2022

Pipeline by Bayer AG, 2022

Pipeline by Betta Pharmaceuticals Co Ltd, 2022

Pipeline by BioArdis LLC, 2022

Pipeline by Blueprint Medicines Corp, 2022

Pipeline by BridgeBio Pharma Inc, 2022

Pipeline by BridGene Biosciences Inc, 2022

Pipeline by Bristol-Myers Squibb Co, 2022

Pipeline by Eddingpharm Inc, 2022

Pipeline by Eisai Co Ltd, 2022

Pipeline by Eli Lilly and Co, 2022

Pipeline by EUSOL Biotech Co Ltd, 2022

Pipeline by Everest Medicines Ltd, 2022

Pipeline by Genosco Inc, 2022

Pipeline by H3 Biomedicine Inc, 2022

Pipeline by Heilongjiang ZBD Pharmaceutical Co Ltd, 2022

Pipeline by ImmunoForge Co Ltd, 2022

Pipeline by InnoCare Pharma Ltd, 2022

Pipeline by Jacobio Pharmaceuticals Group Co Ltd, 2022

Pipeline by Johnson & Johnson, 2022

Pipeline by Merck & Co Inc, 2022

Pipeline by NGM Biopharmaceuticals Inc, 2022

Pipeline by Shouyao Holding Co Ltd, 2022

Pipeline by Tyra Biosciences Inc, 2022

Pipeline by Vichem Chemie Research Ltd, 2022

Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, 2022

Dormant Products, 2022

Dormant Products, 2022 (Contd..1)

Dormant Products, 2022 (Contd..2)

Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$3,500

Can be used by individual purchaser only

$10,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.